San Diego Business Journal

Whistleblower Laws Call for Sound, Clearly Defined Policies

A tidal wave of new lawsuits claiming retaliation against so-called whistleblowers has been hitting business owners in recent years.

By Brittany Meiling August 15, 2014 4:13 p.m. share »

So Long and Thanks for All the Health Care, Biotechnology News

(Editor’s note: This is the final column on biotechnology and health care from Meghana Keshavan, who leaves the San Diego Business Journal as of this issue to join a national online publication focused on innovation in the health care industry.)

By Meghana Keshavan June 13, 2014 3:52 p.m. share »

Pfenex Seeking $74.8M in Initial Public Offering

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering. The company is looking to raise $74.8 million as it focuses development on a growing class of drugs called biosimilars, which are projected to make a large dent in big pharma sales as patents for biologic drugs expire.

By Meghana Keshavan June 13, 2014 3:12 p.m. share »
Tease photo

Isis Pharmaceuticals Gets Multimillion-Dollar Milestone Payment

Isis Pharmaceuticals Inc. has received a large milestone payment from AstraZeneca PLC.

By Meghana Keshavan June 10, 2014 4:18 p.m. share »

Solstice Biologics Names CEO With Boston VC Pedigree

Venture capital veteran from Boston joining San Diego biotech as CEO.

By Meghana Keshavan June 9, 2014 5:10 p.m. share »

Pfenex Inc. Aims for $74.8M IPO

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars.

By Meghana Keshavan June 8, 2014 4:07 p.m. share »

Pfenex Inc. Plans $74.8 M illion IPO

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars.

By Meghana Keshavan June 6, 2014 3:52 p.m. share »

New President, CFO at Celladon Says Co. Ripe to Expand Staff

I chatted recently with Paul Cleveland, a veteran biotech finance guy who has recently been brought on as president and chief financial officer for the newly public gene therapy company Celladon Corp. Cleveland most recently was CFO of Aragon Pharmaceuticals Inc., a San Diego drugmaker sold to Johnson & Johnson last August for $1 billion.

By Meghana Keshavan June 6, 2014 3:07 p.m. share »
Tease photo

Pathway Launches Breast Cancer Test With Philanthropic Twist

San Diego’s Pathway Genomics Corp. is employing a social entrepreneurship model as it launches its new genetic test for breast cancer — entering a market made more high profile and competitive after a U.S. Supreme Court ruling last year that invalidated patents on genes.

By Meghana Keshavan June 6, 2014 2:37 p.m. share »

Covert Stepping Down as CEO of Palomar Health

Michael Covert is stepping down after more than a decade as CEO of Palomar Health, heading to Texas in August to run six Houston-area hospitals.

By Meghana Keshavan June 6, 2014 2:28 p.m. share »
Tease photo

Healthy Appetite

Ayub Khattak’s big idea started with the swine flu.

By Meghana Keshavan June 6, 2014 2:16 p.m. share »

J. Craig Venter Institute to Receive $25M for Studies of Pathogen Genomics

The National Institutes of Health has awarded up to $25 million to the La Jolla-based J. Craig Venter Institute to study the genetics of infectious diseases like malaria and influenza.

By Meghana Keshavan June 5, 2014 4:06 p.m. share »

Halozyme Shares Increase 12% After News That Clinical Trials Can Restart

Shares for Halozyme Therapeutics Inc. surged 12 percent June 5 on news that it will be able to continue clinical trials for its pancreatic cancer treatment, albeit under a revised treatment plan.

By Meghana Keshavan June 5, 2014 4:02 p.m. share »
Tease photo

Illumina to Offer $900M in Convertible Senior Notes

Illumina Inc. intends to offer about $900 million in convertible senior notes, and plans to use the balance of the net proceeds for general corporate purposes.

By Meghana Keshavan June 4, 2014 4:07 p.m. share »
Tease photo

Covert Stepping Down as CEO of Palomar Health

Michael Covert is stepping down after more than a decade as CEO of Palomar Health, and is headed to Texas to run six Houston-area hospitals this August.

By Meghana Keshavan June 4, 2014 4:05 p.m. share »

OncoSec to Sell $16M in Securities in Direct Offering

San Diego cancer drug maker OncoSec Medical Inc. has entered into definitive agreements with institutional investors to purchase about $16 million of securities in a registered direct offering.

By Meghana Keshavan June 4, 2014 4:02 p.m. share »

Pathway Genomics Launches Gene Test for Breast Cancer

San Diego’s Pathway Genomics Corp. has launched test that detects a genetic mutation that causes breast cancer, benefitting from a Supreme Court ruling last year that invalidated patents on genes.

By Meghana Keshavan June 3, 2014 4:04 p.m. share »

Developer Gives $25M to Salk Institute

Area real estate developer Conrad Prebys has given $25 million to the Salk Institute for Biological Studies to support its wide range of medical research.

By Meghana Keshavan June 2, 2014 4:04 p.m. share »

Celladon Appoints Cleveland as New President, CFO

San Diego biotech Celladon Corp. has appointed industry veteran Paul Cleveland as its new president and chief financial officer.

By Meghana Keshavan June 2, 2014 4:02 p.m. share »

Sequenom Sells Bioscience Segment to New Local Company

San Diego-based diagnostic test maker Sequenom Inc. has shed its Bioscience segment. It has been acquired by Agena Bioscience Inc., a newly formed San Diego-based portfolio company of private equity firm Telegraph Hill Partners.

By Meghana Keshavan June 1, 2014 4:04 p.m. share »

Cytori Selling Subscription Agreements to Tune of $10M

San Diego regenerative medicine company Cytori Therapeutics Inc. has entered into subscription agreements with some of its institutional investors to raise about $10 million.

By Meghana Keshavan June 1, 2014 4:03 p.m. share »

Cytori Aims for $10M Through Subscription Agreements Sale

San Diego regenerative medicine company Cytori Therapeutics Inc. has entered into subscription agreements with some of its institutional investors to raise about $10 million.

By Meghana Keshavan May 30, 2014 3:54 p.m. share »

Sequenom Sells Bioscience Segment

San Diego-based diagnostic test maker Sequenom Inc. has shed its Bioscience segment; it has been acquired by Agena Bioscience Inc., a newly formed San Diego-based portfolio company of private equity firm Telegraph Hill Partners.

By Meghana Keshavan May 30, 2014 3:44 p.m. share »

Avalon-GSK Partnership to Welcome 2 More Cos. to the World

I have the hazy outlines of a scoop for you, my dear readers: Two more companies have been born out of Avalon Ventures’ unconventional, $495 million alliance with British pharma giant GlaxoSmithKline PLC, according to Douglas Downs, a managing partner and chief financial officer at Avalon Ventures.

By Meghana Keshavan May 30, 2014 3:39 p.m. share »
Tease photo

International Biotech Convention Will Highlight Region’s Progress

A forthcoming downtown convention will provide a platform for area companies to tout San Diego as one of the country’s most innovative hubs for biotechnology.

By Meghana Keshavan May 30, 2014 3:15 p.m. share »

Volcano Corp. Finds ‘Synergistic Fit’ With AtheroMed Buy

Volcano Corp. has agreed to acquire privately held AtheroMed Inc. for $115 million in cash, setting its sights on the Menlo Park-based company’s devices that help physicians treat peripheral artery disease.

By Meghana Keshavan May 30, 2014 2:55 p.m. share »

Licensing Deals Help Ligand to Stay Lean

Ligand Pharmaceuticals Inc. has forged a creative new licensing deal with a small La Jolla startup — further indication that the once-beleaguered biotech is making a marked turnaround.

By Meghana Keshavan May 30, 2014 2:29 p.m. share »

Venture Capital Lured By San Diego Biotechs

Venture capital investment in San Diego’s life sciences arena is on the upswing, boosted by the lingering positive effects of a bullish biotech market, according to area VCs and a new report from PriceWaterhouseCoopers LLP.

By Meghana Keshavan May 30, 2014 2:25 p.m. share »
Tease photo

Vital Therapies Reports Net Loss of $10.7M for Q1

Vital Therapies Inc. reported a net loss of $10.7 million in its very first quarterly earnings report — the biotech, which is developing treatments for liver failure, began trading on the public markets April 17 with a $61.1 million IPO.

By Meghana Keshavan May 28, 2014 4:04 p.m. share »
Tease photo

Volcano Corp. to Buy AtheroMed for $115M in Cash

San Diego medical device maker Volcano Corp. will acquire privately held AtheroMed Inc. for $115 million in cash, with aims to manufacture and commercialize the Menlo Park company’s devices that treat peripheral artery disease.

By Meghana Keshavan May 27, 2014 4:07 p.m. share »
Tease photo

Powerful Solutions

San Diego’s clean technology sector is flourishing: From solar power and wind technologies to clean transportation, algae-based industrial chemicals and biofuels, the region is lush with companies that are pushing new boundaries in sustainability – and creating new jobs.

By Meghana Keshavan May 23, 2014 3:41 p.m. share »
Tease photo

Degree of Difficulty

Michelle Lee left medical school to pursue her passion for nursing, preferring the more intimate contact nurses tend to have with patients over the “in-and-out” bedside manner she sees as typical of many physicians.

By Meghana Keshavan May 23, 2014 2:23 p.m. share »
Tease photo

Ligand Pharmaceuticals Does Licensing Deal and Investment With San Diego Startup

San Diego-based Ligand Pharmaceuticals Inc. has licensed five of its programs to Viking Therapeutics Inc.; Ligand is also investing $2.5 million in Viking, a San Diego startup.

By Meghana Keshavan May 22, 2014 4:03 p.m. share »

Scripps Partnering With Rady for Hospice Care for Children

Scripps Health is partnering with Rady Children’s Hospital to provide hospice care for children in need of end-of-life care.

By Meghana Keshavan May 20, 2014 4:04 p.m. share »

MabVax-Telik Union Shows How Dramatically Fortunes Change

Privately held San Diego cancer vaccine maker MabVax Inc. has merged with Palo Alto-based Telik Inc. — a once high-flying drugmaker whose reputation and stock value tumbled after drug failures and an ethics controversy.

By Meghana Keshavan May 19, 2014 4:47 p.m. share »

Sorrento Therapeutics Plans to Raise $23.1M With Secondary Stock Offering

Sorrento Therapeutics Inc. has priced its secondary stock offering of 4.765 million shares at $5.25 apiece, with plans to raise net proceeds of $23.1 million.

By Meghana Keshavan May 18, 2014 4:04 p.m. share »
Tease photo

Philanthropist Is Donating $7.5M for New UCSD Cancer Hospital

Area philanthropist Pauline Foster is donating $7.5 million to help build a new cancer care hospital at University of California, San Diego’s Jacobs Medical Center.

By Meghana Keshavan May 18, 2014 4:03 p.m. share »
Tease photo

Philanthropist Donating $7.5 Million for New UCSD Cancer Hospital

Area philanthropist Pauline Foster is donating $7.5 million to help build a new cancer care hospital at University of California, San Diego’s Jacobs Medical Center.

By Meghana Keshavan May 16, 2014 3:47 p.m. share »

Sorrento Therapeutics Prices Secondary Stock -Offering Shares at $5.25

Sorrento Therapeutics Inc. has priced its secondary stock offering of 4.765 million shares at $5.25 apiece, with plans to raise net proceeds of $23.1 million.

By Meghana Keshavan May 16, 2014 3:36 p.m. share »
Tease photo

CleverPet Offers Dog a New Best Friend When Owner Not Home

A San Diego startup may have a solution for Fido’s and Fifi’s errant ways.

By Meghana Keshavan May 16, 2014 3:32 p.m. share »

MabVax-Telik Union Shows How Dramatically Fortunes Change

Privately held San Diego cancer vaccine maker MabVax Inc. has merged with Palo Alto-based Telik Inc. — a once high-flying drugmaker whose reputation and stock value tumbled after drug failures and an ethics controversy.

By Meghana Keshavan May 16, 2014 3:25 p.m. share »

Lumena’s IPO Plans End With Acquisition

Lumena Pharmaceuticals Inc. is being snapped up by Irish drugmaker Shire PLC for $260 million, scrapping the San Diego biotech’s plan to raise $75 million in an initial public offering.

By Meghana Keshavan May 16, 2014 2:43 p.m. share »
Tease photo

CareFusion Prices $1 Billion of Senior Unsecured Notes

San Diego medical device maker CareFusion Corp. has priced three series of senior unsecured notes for an aggregate principal amount of $1 billion.

By Meghana Keshavan May 15, 2014 5:06 p.m. share »

Some Area Hospitals, Clinics Close Due to Fire Danger

There have been a spate of health center closings in the wake of the area wildfires – two Palomar Health clinics in San Marcos closed May 15, and the Scripps Coastal Medical Center in Carlsbad shut down May 14.

By Meghana Keshavan May 15, 2014 5:04 p.m. share »

Isis Pharmaceuticals Gets $3M Milestone Payment

Isis Pharmaceuticals Inc. received a $3 million milestone payment from GlaxoSmithKline PLC for starting a study that ties into its partnership to develop three new drugs using Isis’ proprietary antisense technology.

By Meghana Keshavan May 15, 2014 5:03 p.m. share »

Human Longevity Inc. Fills Leadership Roles

Human Longevity Inc., the J. Craig Venter-backed outfit that recently raised $70 million in Series A to help extend the human lifespan through genomics and informatics, has a trio of new hires to pad its C-Suite.

By Meghana Keshavan May 14, 2014 4:04 p.m. share »

Sorrento Therapeutics Proposes Common Stock Offering

Sorrento Therapeutics Inc. has announced a proposed offering of its common stock, but hasn’t disclosed the size of the offering.

By Meghana Keshavan May 14, 2014 4:02 p.m. share »

MabVax, Telik Conduct Reverse Merger

Privately held San Diego cancer vaccine maker MabVax Inc. has merged with Palo Alto-based Telik Inc. – a once high-flying drugmaker whose reputation and stock value tumbled after drug failures and an ethics controversy.

By Meghana Keshavan May 13, 2014 4:08 p.m. share »

Parametric Sound Reports Increase in Revenue, Gross Profit

San Diego audio headset maker Parametric Sound Corp. has grown both its revenue and its profit for the first quarter of 2014, as it gears up to complete a merge with Turtle Beach Corp.

By Meghana Keshavan May 13, 2014 4:03 p.m. share »
Tease photo

Arena Pharmaceuticals Reports Q1 Loss of $25.3M

Despite reporting strong first quarter sales for its weight-loss drug, Belviq, San Diego’s Arena Pharmaceuticals Inc.’s net loss increased compared with the like reporting period of the previous year.

By Meghana Keshavan May 12, 2014 4:04 p.m. share »

Prev

Page of .